Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous NK Cell Immunotherapy in Advanced Lung Adenocarcinoma
NCT03662477Phase 1Unknown
- Sponsor
- Luohu District People's Hospital
- Start
- Jan 2018
- Primary completion
- Dec 2019
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of troculeucel in lung adenocarcinoma (4 arms), sponsored by Luohu District People's Hospital. Primary endpoint: Clinical Response (Sum of Tumor Areas) at 3 months. Status: unknown.
02
Drugs
troculeucel
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT03662477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03662477.